

Technology Advisory Committee D Interests Register

Belumosudil for treating chronic graft versus host disease after 2 or more lines of systemic therapy [ID4021]

Publication Date: 07/02/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David Meads	Committee Member	Direct - Non-Financial Professional	David's employer, the University of Leeds, has received funding from Sanofi for research into myeloma. That relates to treatment of the disease rather than stem cell grafts.	30/08/2023 16/11/2023	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Daniel Yates	Patient expert	Indirect – Financial	Anthony Nolan are in discussion with Sanofi regarding consulting on a graft-versus-host disease patient market study but none of the people involved in that have had direct contact with the appraisal submissions. Pfizer paid a patient connected to Anthony Nolan, a member of their policy patient insight panel (not Daniel), and an Anthony Nolan employee honorarium for attending a workshop on developing a blood cancer patient charter.	30/08/2023 13/09/2023	It was agreed that Daniel's declaration would not prevent him from providing expert advice to the committee.
Adrian Bloor	Clinical expert	Direct - Professional	Adrian is UK Chief Investigator for the Sanofi EFC17757 trial of belumosudil in combination with corticosteroids versus placebo in combination with	30/08/2023 13/09/2023	It was agreed that Adrian's declaration would not prevent him from providing

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			corticosteroids for patients with newly diagnosed chronic graft versus host disease. He has had no involvement in any of the studies considered in the NICE technology appraisal (ROCKstar, REACH-3 or NCT02841995) and has not participated in any Sanofi advisory boards.		expert advice to the committee.
Dr Jose Ros-Soto	Clinical expert	Direct – Professional	Dr Ros-Soto has been a speaker for Therakos, the company that provides the machines for electrocorporeal photoapheresis (ECP)	13/09/2023	It was agreed that Jose's declaration would not prevent him from providing expert advice to the committee.